Home › Merck Receives Positive CHMP Opinion for ZEPATIER (elbasvir and grazoprevir) in the European Union
 

Keywords :   


Merck Receives Positive CHMP Opinion for ZEPATIER (elbasvir and grazoprevir) in the European Union

2016-05-27 13:46:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of ZEPATIER (elbasvir and grazoprevir), an investigational, once-daily, fixed-dose combination tablet for the treatment of chronic hepatitis C virus (HCV) in adult patients. The CHMP positive opinion will be reviewed by the European Commission. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orSarra Herzog, 908-740-1871orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the positive opinion union

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.04This Week in Agribusiness, April 20, 2024
20.04This Week in Agribusiness, April 20, 2024
20.04App to cut EU border queues won't be ready in time
19.04PPG Board of Directors Announce Quarterly Dividend of 65 Cents Per Share
19.04Can AI help solve Japans labour shortages?
19.04 PPG Board of Directors Authorizes $2.5 Billion Share Repurchase Program
19.04Warning jailed bankers ruling could hit loan rate
19.04NFU Statement on EPA E15 Announcement
More »